论文部分内容阅读
[目的]探讨吉非替尼在Ⅳ期非小细胞肺癌(NSCLC)患者化疗中的疗效.[方法]在本院治疗的Ⅳ期NSCLC患者72例,根据不同治疗方案分为观察组(n=34)和对照组(n=38),对照组给予顺铂联合培美曲赛治疗,观察组给予顺铂联合吉非替尼治疗,比较两组疗效及对肿瘤标志物的影响.[结果]观察组总有效率为91.18%(31／34),明显优于对照组的81.58%(31／38),且差异有显著性(P<0.05).观察组骨髓抑制、腹泻的发生率明显高于对照组(P<0.05).观察组治疗后癌胚抗原(CEA)、细胞角蛋白片段21-1(CYFRA21-1)及鳞状细胞癌抗原(SCCA)明显低于对照组(P<0.05);观察组中位无进展生存时间和总体生存期分别为9个月和13个月,明显高于对照组5个月和9个月(P<0.05).[结论]Ⅳ期NSCLC患者采用吉非替尼化疗有较好的临床疗效,可显著降低CEA、CYFRA21-1及SCCA水平,值得临床使用.“,”[Objective]ToinvestigatetheeffectofgefitinibinthetreatmentofstageIVnon-smaLLceLLLung cancer(NSCLC).[Methods]AtotaLof72patientswithstageIV NSCLCinourhospitaLweredividedintothe observationgroup (n=34)andthecontroLgroup (n=38).PatientsinthecontroLgroupweretreatedwith cispLatinpLuspimitrex,whiLepatientsintheobservationgroupweregivencispLatinpLusgefitinib.Thethera-peuticeffectsandtumormarkerchangesinthetwogroupswerecompared.[ResuLts]Theshort-termcurative effectoftheobservationgroupwassignificantLybetterthanthatofthecontroLgroup (P<0.05),whichof cLinicaLeffectiverateswere91.18% and81.58%,respectiveLy;Theratesofbonemarrowsuppressionanddi-arrheaintheobservationgroupweresignificantLyhigherthanthoseinthecontroLgroup (P<0.05);After treatment,theparacancerousantigen (CEA),cytokeratinfragment21-1 (CYFRA21-1)andsquamousceLL carcinomaantigen (SCCA)intheobservationgroupwere(30.03±11.02)g／L,(25.58±6.22)g／Land(25.50 ±5.44)g／L,respectiveLy,whichweresignificantLyLowerthanthoseofthecontroLgroup(P<0.05).Theme-dian progression-freesurvivaLtimeand overaLLsurvivaLintheobservation group were9 monthsand13 months,respectiveLy,which weresignificantLyLongerthanthoseinthecontroLgroup (5 monthsand9 months,respectiveLy)(P<0.05).[ConcLusion]GefitinibhasgoodcLinicaLefficacyinthetreatmentofstageⅣnon-smaLLceLLLungcancerpatients,whichcansignificantLyreduceCEA,CYFRA21-1andSCCALeveLs.It isworthyofcLinicaLuse.